Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 14/20 | 0.75 |
| ▸ | GRPR | P30550 | 1/20 | 0.69 |
| ▸ | GLP1R | P43220 | 3/20 | 0.68 |
| ▸ | CCKBR | P32239 | 1/20 | 0.68 |
| ▸ | ECE1 | P42892 | 1/20 | 0.66 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.66 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773403 | 0.91 | PTH1R (0.85) | PTH1RGLP1RCCKBRECE1MUS81 | |
| Teriparatide SCHEMBL29354459 | 0.89 | PTH1R (0.91) | PTH1RGLP1RCCKBRECE1MUS81 | |
| SCHEMBL28980015 | 0.89 | PTH1R (0.91) | PTH1RGLP1RCCKBRECE1MUS81 | |
| Teriparatide SCHEMBL720581 | 0.89 | PTH1R (0.90) | PTH1RGLP1RCCKBRECE1MUS81 | |
| SCHEMBL29694495 | 0.89 | PTH1R (0.78) | PTH1RGLP1RCCKBRECE1MUS81 | |
| Teduglutide SCHEMBL29373256 | 0.87 | GLP1R (0.82) | PTH1RGLP1RCCKBRECE1MUS81 | |
| SCHEMBL29664425 | 0.87 | GLP1R (0.72) | PTH1RGLP1RCCKBRECE1MUS81 | |
| SCHEMBL29376455 | 0.87 | PTH1R (0.81) | PTH1RGLP1RCCKBRECE1MUS81 | |
| Teduglutide SCHEMBL20898050 | 0.87 | GLP1R (0.82) | PTH1RGLP1RCCKBRECE1MUS81 | |
| SCHEMBL29694499 | 0.86 | PTH1R (0.72) | PTH1RGLP1RCCKBRECE1MUS81 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069529-A1 | TOPICAL COMPOSITIONS OF MICROCOCCUS LUTEUS Q24 AND USE THEREOF | BLIS TECH LIMITED (NZ) | 2026-03-12 | — | — | US | claimed |
| EP-4580597-A1 | TOPICAL COMPOSITIONS OF MICROCOCCUS LUTEUS Q24 AND USE THEREOF | Blis Technologies Limited (NZ) | 2025-07-09 | — | — | EP | claimed |
| WO-2024047589-A1 | TOPICAL COMPOSITIONS OF MICROCOCCUS LUTEUS Q24 AND USE THEREOF | BLIS TECHNOLOGIES LIMITED (NZ) | 2024-03-07 | — | — | WO | claimed |
| EP-4301332-A1 | TOPICAL COMPOSITION AND USE THEREOF | Blis Technologies Limited (NZ) | 2024-01-10 | — | — | EP | claimed |
| CN-117304334-A | Streptococcus salivarius antibacterial peptide and preparation method and application thereof | 大连医科大学 | 2023-12-29 | — | — | CN | claimed |
| CN-115991750-A | Application of salicin in preparation of IL-21 receptor inhibitor | 北京大学人民医院 | 2023-04-21 | — | — | CN | claimed |
| CN-115779069-A | Application of salivaricin in preparation of IL-6 receptor inhibitor | 北京大学人民医院 | 2023-03-14 | — | — | CN | claimed |
| WO-2022185238-A1 | TOPICAL COMPOSITION AND USE THEREOF | BLIS TECHNOLOGIES LIMITED (NZ) | 2022-09-09 | — | — | WO | claimed |
| US-20260069529-A1 | TOPICAL COMPOSITIONS OF MICROCOCCUS LUTEUS Q24 AND USE THEREOF | BLIS TECH LIMITED (NZ) | 2026-03-12 | — | — | US | disclosed |
| US-20260053868-A1 | METHOD OF USING A COMPOSITION COMPRISING A NOVEL STREPTOCOCCUS SALIVARIUS STRAIN IN PREVENTING OR ALLEVIATING AN ORAL DISEASE | GREENSTORE INC. (KR) | 2026-02-26 | — | — | US | disclosed |
| US-12480089-B2 | Antiviral treatment comprising Blis containing probiotic products | BLIS TECHNOLOGIES LIMITED (NL) | 2025-11-25 | — | — | US | disclosed |
| WO-2025227220-A1 | S. SALIVARIUS STRAIN, LANTHIPEPTIDES AND METHODS OF USE | Ostia Sciences Inc. (CA) | 2025-11-06 | — | — | WO | disclosed |
| EP-4580597-A1 | TOPICAL COMPOSITIONS OF MICROCOCCUS LUTEUS Q24 AND USE THEREOF | Blis Technologies Limited (NZ) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025132965-A1 | FORMULATIONS AND DEVICES COMPRISING LANTIBIOTIC-PRODUCING BACTERIA | REICHARDT ELISABETH (DE) | 2025-06-26 | — | — | WO | disclosed |
| WO-2022185238-A1 | TOPICAL COMPOSITION AND USE THEREOF | BLIS TECHNOLOGIES LIMITED (NZ) | 2022-09-09 | — | — | WO | disclosed |
| US-11421223-B2 | Processes and host cells for genome, pathway, and biomolecular engineering | ENEVOLV, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-11406674-B2 | Composition comprising new Lactobacillus salivarius strains and method for the prevention and treatment of otitis and upper respiratory infections | Probisearch, S.L.U. (ES) | 2022-08-09 | — | — | US | disclosed |
| WO-2022164306-A1 | MATRIX FORMULATED WITH PROBIOTICS FOR USE IN THE TREATMENT OF CARIES | INSTITUTO TECNOLÓGICO Y DE ESTUDIOS SUPERIORES DE OCCIDENTE, A.C. (MX) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022096573-A1 | NEW COMPOSITION FOR TREATMENT OF SKIN CONDITIONS | LACTOBIO A/S (DK) | 2022-05-12 | — | — | WO | disclosed |
| CN-109675017-B | Application of streptococcus salivarius in preparing medicine for preventing and/or treating autoimmune disease | 北京大学人民医院(北京大学第二临床医学院) | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069529-A1 | TOPICAL COMPOSITIONS OF MICROCOCCUS LUTEUS Q24 AND USE THEREOF | LIPA, LPL, LCT | PTH1R 3923/4885GRPR 4301/4885GLP1R 2404/4885 |
| US-20260053868-A1 | METHOD OF USING A COMPOSITION COMPRISING A NOVEL STREPTOCOCCUS SALIVARIUS STRAIN IN PREVENTING OR ALLEVIATING AN ORAL DISEASE | CLPP, MMP8, CFL1 | PTH1R 1850/4885GRPR 3834/4885GLP1R 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.